ArticleJournal of cancer research and clinical oncology2014
Extracranial glioblastoma in transplant recipients.
Article in Journal of cancer research and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Beyond the Brain: Circulating Tumor Cells as a Tool for Diagnosis and Monitoring.JCO precision oncology · 2026Article
- Extraneural metastases of glioblastoma: A case report and literature review.Surgical neurology international · 2025Article
- Metastatic glioblastoma to the lungs: a case report and literature review.CNS oncology · 2024Review
- Innovative Approach to Isolate and Characterize Glioblastoma Circulating Tumor Cells and Correlation with Tumor Mutational Status.International journal of molecular sciences · 2023Article
- Extra-neural metastases in pediatric diffuse midline gliomas, H3 K27-altered: presentation of two cases and literature review.Frontiers in molecular neuroscience · 2023Article
- Risk factors of extraneural spreading in astrocytomas and oligodendrogliomas in donors with gliomas: A systematic review.World journal of transplantation · 2022Article
- Rapid screening for safety of donation from donors with central nervous system malignancies.Medicine · 2020Review
- Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape.Acta neuropathologica communications · 2020Article
- Autologous and Pooled Tumor Lysates in Combined Immunotherapy of Patients with Glioblastoma.Sovremennye tekhnologii v meditsine · 2020Article
- Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening.Frontiers in immunology · 2020Review
- Secondary glioblastoma metastasis outside the central nervous system in a young HIV-infected patient.Therapeutic advances in medical oncology · 2020Article
- Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein.Cells · 2019Article
- Dormant tumour cells, their niches and the influence of immunity.Nature cell biology · 2018Review
- Cancer Metastases: Early Dissemination and Late Recurrences.Cancer growth and metastasis · 2015Review
- Targeting adaptive glioblastoma: an overview of proliferation and invasion.Neuro-oncology · 2014Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTraditionally, gliomas are considered to be confined to the central nervous system. The shortage of solid donor organs resulted in consideration of organs from patients with primary malignancy such as glioblastoma multiforme (GBM) for transplantation into patients suffering from end-stage organ disease.
methodsWe performed a PubMed search including all studies that documented patient demographics, pre- and post-transplantation conditions as well as time to metastasis and overall survival in recipients of organ transplants from donors suffering from GBM.
resultsA total of 11 studies with 11 patients were included in this review. Three patients had liver, three had kidney, and five had lung transplantation. For kidney transplants, average time to metastasis was 17.3 months post-surgery. The average follow-up time was 32.3 months, and all patients were doing well. All liver transplant recipients succumbed due to GBM metastasis. The average survival was 7 months for all three patients. For lung-receiving patients, two patients died at an average of 9.5 months post-transplantation, with a mean time to metastasis of 9 months. Two patients were doing well at 17- and 20-month follow-up. One patient was diagnosed with metastasis 12 months after transplantation, but no follow-up data were provided.
conclusionsThese studies emphasize the disadvantage of transplanting an organ of an individual with GBM. However, it should be noted that these cases do not make up a large percentage of overall transplantations, and donors with primary central nervous system malignancies also do not represent the whole pool of organs available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.